Literature DB >> 12399141

Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils in vitro.

Kenjiro Ono1, Kazuhiro Hasegawa, Masahito Yamada, Hironobu Naiki.   

Abstract

BACKGROUND: Cerebral deposition of amyloid beta-peptide (Abeta) is a major neuropathologic feature in Alzheimer's disease (AD). A consistent protective effect of smoking on AD has been documented by many case-control studies. It has been suggested that nicotine, a major component of cigarette smoke, protects neurons against Abeta toxicity via the upregulation of nicotinic receptors, as well as via the inhibition of beta-amyloid fibril (fAbeta) formation from Abeta.
METHODS: We used fluorescence spectroscopy with thioflavin T and electron microscopy to examine the effects of nicotine, pyridine, and N-methylpyrrolidine on the formation, extension, and disruption of fAbeta(1-40) and fAbeta(1-42) at pH 7.5 at 37 degrees C in vitro.
RESULTS: Nicotine dose-dependently inhibited fAbeta(1-40) and fAbeta(1-42) formation from fresh Abeta(1-40) and Abeta(1-42), respectively, as well as the extension reaction of both fAbetas. Moreover, nicotine disrupted preformed fAbeta(1-40) and fAbeta(1-42). These effects of nicotine were observed at concentrations above 10 mmol/L and were similar to those of N-methylpyrrolidine.
CONCLUSIONS: The antiamyloidogenic effect of nicotine may be exerted not only by the inhibition of fAbeta formation but also by the disruption of preformed fAbeta. Additionally, this effect may be attributed to N-methylpyrrolidine moieties of nicotine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12399141     DOI: 10.1016/s0006-3223(02)01417-8

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  25 in total

Review 1.  Natural products as a source of Alzheimer's drug leads.

Authors:  Philip Williams; Analia Sorribas; Melanie-Jayne R Howes
Journal:  Nat Prod Rep       Date:  2010-11-12       Impact factor: 13.423

2.  Targeted studies on the interaction of nicotine and morin molecules with amyloid β-protein.

Authors:  Subramaniam Boopathi; Ponmalai Kolandaivel
Journal:  J Mol Model       Date:  2014-02-25       Impact factor: 1.810

Review 3.  Basal forebrain cholinergic dysfunction in Alzheimer's disease--interrelationship with beta-amyloid, inflammation and neurotrophin signaling.

Authors:  Reinhard Schliebs
Journal:  Neurochem Res       Date:  2005 Jun-Jul       Impact factor: 3.996

4.  The influence of phospholipid membranes on bovine calcitonin secondary structure and amyloid formation.

Authors:  Steven S-S Wang; Theresa A Good; Dawn L Rymer
Journal:  Protein Sci       Date:  2005-05-09       Impact factor: 6.725

Review 5.  The significance of the cholinergic system in the brain during aging and in Alzheimer's disease.

Authors:  R Schliebs; T Arendt
Journal:  J Neural Transm (Vienna)       Date:  2006-10-13       Impact factor: 3.575

6.  Inflammation and oxidative stress induced by cigarette smoke in Lewis rat brains.

Authors:  A Khanna; M Guo; M Mehra; W Royal
Journal:  J Neuroimmunol       Date:  2012-09-30       Impact factor: 3.478

Review 7.  Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease.

Authors:  Ghiam Yamin; Kenjiro Ono; Mohammed Inayathullah; David B Teplow
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

8.  Nicotine reduces the cytotoxic effect of glycated proteins on microglial cells.

Authors:  Mohammad R Khazaei; Mostafa Bakhti; Mehran Habibi-Rezaei
Journal:  Neurochem Res       Date:  2009-11-28       Impact factor: 3.996

9.  Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-beta aggregation pathway.

Authors:  Tsuyoshi Hamaguchi; Kenjiro Ono; Atsushi Murase; Masahito Yamada
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

10.  Neuroprotection of rat retinal ganglion cells mediated through alpha7 nicotinic acetylcholine receptors.

Authors:  K Iwamoto; D Mata; D M Linn; C L Linn
Journal:  Neuroscience       Date:  2013-02-10       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.